{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:59:52Z","timestamp":1788026392467,"version":"build-2784847793"},"reference-count":120,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T00:00:00Z","timestamp":1689465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Atopic dermatitis (AD) is a chronic, inflammatory, intensely pruritic skin disorder associated with significant patient burden. Interleukin (IL)\u201013 is a cytokine that acts as a driver of immune dysregulation, skin\u2010barrier dysfunction, and microbiome dysbiosis that characterizes AD, and is consistently overexpressed in AD skin. Tralokinumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody that binds specifically to IL\u201013 with high affinity, thereby inhibiting subsequent downstream IL\u201013 signaling. Three pivotal phase 3 clinical trials demonstrated that tralokinumab 300\u2009mg every other week, as monotherapy or in combination with topical corticosteroids as needed, provides significant improvements in signs and symptoms of moderate\u2010to\u2010severe AD, as measured by Investigator's Global Assessment 0\/1 (clear\/almost clear) and Eczema Area and Severity Index\u201075 at Week 16. Improvements were observed soon after tralokinumab initiation and were maintained over 52\u2009weeks of therapy. Tralokinumab significantly improved patient\u2010reported outcomes such as itch and sleep, and demonstrated a safety profile comparable with placebo; conjunctivitis during tralokinumab therapy was generally mild. Similar results were observed in a phase 3 adolescent trial. The role of IL\u201013 in the pathophysiology of AD justifies a targeted approach and a wealth of clinical data supports tralokinumab as a new therapeutic option for people with moderate\u2010to\u2010severe AD.<\/jats:p>","DOI":"10.1111\/all.15811","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:20:37Z","timestamp":1689553237000},"page":"2875-2891","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Tralokinumab therapy for moderate\u2010to\u2010severe atopic dermatitis: Clinical outcomes with targeted\n                    <scp>IL<\/scp>\n                    \u201013 inhibition"],"prefix":"10.1111","volume":"78","author":[{"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[{"name":"Department of Dermatology Oregon Health and Science University  Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman\u2010Yassky","sequence":"additional","affiliation":[{"name":"Department of Dermatology and the Immunology Institute Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Pediatrics University of California San Diego and Rady Children's Hospital San Diego  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[{"name":"Division of Allergy\u2010Immunology, Department of Pediatrics National Jewish Health and University of Colorado School of Medicine  Denver Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-3817","authenticated-orcid":false,"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Christine K\u00fchne\u2014Center for Allergy Research and Education (CK\u2010CARE) University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Schneider","sequence":"additional","affiliation":[{"name":"LEO Pharma  Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Guana","sequence":"additional","affiliation":[{"name":"LEO Pharma  Madison New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology George Washington University School of Medicine  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16892"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.028"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.325"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.530"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.019"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.012"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.08.022"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09207-z"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.07.018"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.1572"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.08.005"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.039"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.10.013"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.048"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000455"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15608"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0627"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13954"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13120"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2017.08.008"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.427"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.036"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.06.032"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.031"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70246-4"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13160"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.018"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.012"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.041"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1159\/000448400"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-004-0455-6"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.047"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.01.001"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15423"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.08.015"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14389"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3831"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.138"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14490"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.039"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.05.008"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.01.003"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.07.007"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.01.042"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130351"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12464"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.05.023"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.12.030"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00888"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102760"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.006"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13911"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890701449354"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2010.01.003"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.01.005"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133324"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2010.24"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2017.02.005"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01067-0"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98006"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.04.031"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.11.006"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3810"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2015.11.007"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.08.008"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.04.022"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.361"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16097"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.05.028"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15973"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.028"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.12.033"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.05.049"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.09.037"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2983"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.08.024"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2016.12.005"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1039\/c3mb70298g"},{"issue":"4","key":"e_1_2_8_90_1","first-page":"1103","article-title":"IL\u201013R(alpha)2, a decoy receptor for IL\u201013 acts as an inhibitor of IL\u20104\u2010dependent signal transduction in glioblastoma cells","volume":"62","author":"Rahaman SO","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1332"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12752"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100214"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2013.01.024"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00266-6"},{"key":"e_1_2_8_96_1","doi-asserted-by":"crossref","unstructured":"WulurI Van HornRD RyuzojiA et al.Lebrikizumab allows interleukin (IL)\u201013 membrane binding and subsequent internalization through IL\u201013 receptor alpha 2 (R\u03b12) (IL\u201013 decoy receptor).2021Paper presented at: Inflammatory Skin Disease Summit (ISDS); 3\u20136 November 2021 New York City USA.","DOI":"10.26226\/m.62fa0091165d7b0019592ac8"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.029"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.07.007"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.6.supp.s29"},{"key":"e_1_2_8_100_1","volume-title":"Western Society of Allergy, Asthma and Immunology","author":"Soong W","year":"2022"},{"key":"e_1_2_8_101_1","unstructured":"SimpsonE ThyssenJP FlohrC et al.Tralokinumab provides progressive improvements beyond week 16 in patients with atopic dermatitis with an initial partial response. In EADV Virtual Congress 29\u201331 October. P0214 ed2020."},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00702-2"},{"key":"e_1_2_8_103_1","unstructured":"AlexisAF ZirwasM PinterA et al.Progressive and sustained improvements in the extent and severity of atopic dermatitis with tralokinumab in combination with topical corticosteroids as needed in moderate\u2010to\u2010severe atopic dermatitis. Paper presented at: 3rd revolutionizing atopic dermatitis virtual conference 2020; Chicago IL."},{"key":"e_1_2_8_104_1","unstructured":"ElewskiBE St\u00e4nderS ZirwasM et al.Early and sustained improvements in patient\u2010reported outcomes with tralokinumab in combination with topical corticosteroids as needed in moderate\u2010to\u2010severe atopic dermatitis.2020Paper presented at: revolutionizing atopic dermatitis (RAD) virtual conference; 13\u201314 December 2020."},{"key":"e_1_2_8_105_1","unstructured":"Guttman\u2010YasskyE ZirwasM KabashimaK et al.Neutralizing interleukin\u201013 with tralokinumab shifts the molecular phenotype of lesional skin towards that of non\u2010lesional skin and restores barrier abnormalities.2021Paper presented at: revolutionizing atopic dermatitis (RAD); 13 June 2021."},{"key":"e_1_2_8_106_1","doi-asserted-by":"crossref","unstructured":"Guttman\u2010YasskyE KabashimaK PavelA Staumont\u2010Sall\u00e9D JiangL.Effects on Type 2 immunity when specifically targeting the interleukin\u201013 cytokine with tralokinumab (ECZTRA 1).2021Paper presented at: American Academy of Dermatology Association Virtual Meeting Experience (AAD VMX).","DOI":"10.1016\/j.jaad.2021.06.314"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.5.supp.56"},{"key":"e_1_2_8_108_1","unstructured":"Guttman\u2010YasskyE PavelA KabashimaS et al.Long\u2010term treatment with tralokinumab normalizes the molecular gene signature of atopic dermatitis.2021Paper presented at: Inflammatory Skin Disease Summit (ISDS); 3\u20136 November 2021."},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0287-7"},{"key":"e_1_2_8_110_1","unstructured":"SilverbergJI BarbarotS WelzelJ et al.Tralokinumab Prevents Flares in Moderate\u2010to\u2010Severe Atopic Dermatitis: Post Hoc Analyses of a Randomized Phase 3 Clinical Trial (ECZTRA 3). Paper presented at: Revolutionizing Atopic Dermatitis (RAD) Virtual Conference; 13\u201314 December 20202020."},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20832"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20810"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21867"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00192.x"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00990-15"},{"key":"e_1_2_8_116_1","first-page":"S0190\u20109622(23)0","article-title":"Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: a review","author":"Shi VY","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_8_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.019"},{"key":"e_1_2_8_118_1","doi-asserted-by":"crossref","unstructured":"LangleyR ReichK SimpsonE et al.Long\u2010term improvements in disease severity itch and quality of life after 3\u2009years of tralokinumab treatment in adults with moderate\u2010to\u2010severe atopic dermatitis.2022In revolutionizing atopic dermatitis.","DOI":"10.26226\/m.63185c4d7e215f5e7f3850b5"},{"key":"e_1_2_8_119_1","doi-asserted-by":"crossref","unstructured":"BlauveltA LangleyR SimpsonE et al.Long\u2010Term Safety and Efficacy of Tralokinumab in More than 1400 Moderate\u2010to\u2010Severe Atopic Dermatitis Patients Treated for up to 42 Months: an Interim Analysis of ECZTEND.2022Paper presented at: American Academy of Dermatology; March 25\u201329 2022.","DOI":"10.1016\/j.jaad.2022.06.754"},{"key":"e_1_2_8_120_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3488"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.032"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.15811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T07:15:08Z","timestamp":1699600508000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.15811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,16]]},"references-count":120,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/all.15811"],"URL":"https:\/\/doi.org\/10.1111\/all.15811","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,16]]},"assertion":[{"value":"2023-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}